Organic Active Ingredients TRIZ Cases

Small-molecule TLR7/9 antagonists suppress TNF-α and other inflammatory cytokines, supporting treatment of lupus, psoriasis, and related diseases.

dsRNA molecules silence TMPRSS6 through the RISC pathway to lower serum iron, ferritin, and transferrin saturation in iron overload disorders.

ALA-based compositions enhance checkpoint inhibitor tumor killing while limiting HO-1-driven PD-L1 upregulation and ROS loss.

A non-aqueous soft gel carrier using medium chain triglycerides and phospholipids improves nintedanib solubility, bioavailability, and dissolution.

Cyclodextrin-based excipients keep levcromakalim soluble and stable in a clear ocular solution without toxic solvent levels or prodrug complexity.

Controlling iron and aldehyde or ketone impurities in glycerin helps protect amino acid, peptide, and protein formulations from oxidative degradation.

Localized topical delivery of (1S)-1-phenyl-2-pyridin-2-ylethanamine relieves neuropathic pain while limiting systemic side effects.

Modified ACE-tRNAs reassign stop codons and improve EF1α interaction to restore full-length protein translation in nonsense mutation diseases.

An in-situ click-crosslinked hydrogel scavenges excess nitric oxide locally and triggers site-specific drug release to limit systemic toxicity.

Novel benzooxazinone and benzothiazinone derivatives inhibit ASK-1 to address fibrosis, kidney disease, and other ASK-1 mediated disorders.

Cyclodextrin inclusion complexes protect unstable SPM triene structures from heat- and humidity-driven isomerization, preserving purity and activity.

A nasal blend of glutathione, PQQ, oils, and oxymetazoline addresses the safety-efficacy tradeoff while delivering rapid respiratory relief.

Monovalent ALK molecular glues recruit E3 ligase at distal sites to degrade wild-type and resistant ALK beyond TKI binding limits.

Esterified creatine and betaine compounds improve solubility and permeability to reduce viral hyper-inflammation and support immune defense.

Stepwise reagent and catalyst optimization raises yield and cuts cycle time in pharmaceutical synthesis of a deuterated TYK2 inhibitor.

Inducible MyD88/CD40 costimulation helps PSCA CAR-T cells persist longer in solid tumors while boosting antitumor activity and limiting toxicity.

Combining hydroxylaminopropylphosphonic acid derivatives with clindamycin and artesunate improves cerebral malaria treatment while limiting side effects.

A biodegradable ocular hydrogel implant sustains TKI release for months while avoiding drug burst, retinal particle contact, and implant residues.

Modified tryptamine compounds such as EPT and MET target mood disorders while limiting psychoactive effects and tuning duration for guided therapy.

Structural changes in heterocyclic GLP-1 agonists improve metabolic stability, sustaining insulin secretion and glucose control in T2DM.

Substituted benzothiophene SERDs degrade ERα, including resistant mutant receptors, to extend endocrine treatment effectiveness in breast cancer.

Aceclidine eye drops improve near vision in presbyopia while reducing dependence on glasses or contacts for at least 10 hours.

Combining anti-CD40 antibodies with chemotherapy boosts immune activation and helps overcome resistance in pancreatic cancer.

Liposomal alpha polyglutamated aminopterin improves tumor selectivity, bypasses resistance mechanisms, and reduces toxicity to normal tissues.

Aceclidine eye drops improve near vision in presbyopia through a reversible miotic effect, reducing reliance on lenses and surgery.

Sterol adjuvants boost antigen-specific immunity, cytokine production, and antibody titers while reducing injection site pain and inflammation.

Biomarker expression profiling helps predict multiple myeloma progression and chemoresistance, guiding targeted treatment selection.

Gatekeeper-mutated kinases let specific inhibitors modulate engineered T-cells while preserving wild-type kinase activity and immune integrity.

Branched-chain amino acids normalize hippocampal amino acid levels to restore memory and cognitive function after traumatic brain injury.

A pH-controlled blend of alpha hydroxy acid, volatile emollient, and processed oat improves eczema skin hydration, feel, and appearance.

Controlled hydroxypropyl beta-cyclodextrin purification removes endotoxin, propylene glycol, and unsubstituted molecules for chronic CNS dosing.

Single-stranded REVERSIR oligonucleotides bind dsRNA agents to rapidly reverse RNAi silencing and help manage dosing side effects.

Co-administered bupropion slows dextromethorphan metabolism, extending plasma half-life, reducing adverse events, and enabling less frequent dosing.

A non-peptide pyrazolopyridine-indole compound delivers oral GLP-1 receptor agonist activity while improving metabolic stability and bioavailability.

Porous solid carriers adsorb cannabinoids to improve oral solubility, stability, rapid release, and more consistent bioavailability.

Sulfur-containing nucleoside prodrugs bypass rate-limiting phosphorylation and improve delivery into viral sanctuaries to address resistance.

Transglutaminase creates defined glutamine attachment sites, and Diels-Alder coupling turns them into homogeneous antibody-drug conjugates.

Selective Formula I RAF inhibitors modulate aberrant MAPK/ERK signaling in tumors while addressing efficacy, resistance, and toxicity.

Antibody-linked glucocorticoids target specific cells to preserve anti-inflammatory efficacy while reducing off-target toxicities.

Encapsulating LPS in liposomes curbs toxicity while boosting NK cells and anti-tumor activity in combination with antibodies or chemotherapy.

Removing propylene glycol, endotoxin, and unsubstituted beta-cyclodextrin enables safer chronic intrathecal or intracerebroventricular use.

A pan-PPAR active composition suppresses neuroinflammation, Aβ aggregation, and gliosis to address cognitive decline in degenerative brain disease.

Small molecules that bind and degrade TRAP1 restore apoptosis, disrupt mitochondrial potential, and reduce oxygen use in cancer cells.

Engineered effector proteins and guide nucleic acids improve target nucleic acid detection and editing for disease-linked mutations.

Liposome nanoparticles deliver BFL1 inhibitors to activated neutrophils, reducing off-target immune effects in inflammation and cancer.

Lipid and amino acid surface treatment stabilizes silicon nanoparticles for controlled active release while preventing OSA polymerization.

A fixed-dose niclosamide and spironolactone composition offers a veterinary option for feline infectious peritonitis where prior antivirals failed.

A table-top sonication process forms inhalable CDK9 microparticles without costly spray drying, enabling small-batch pulmonary R&D.

A benzene-ring compound uses tailored substituents and heteroatoms to inhibit P2X4 with better selectivity, lower toxicity, and metabolic stability.

A p53-reactivating compound paired with MDM2 inhibition restores mutant p53 activity and improves anti-tumor response in p53-mutant cancers.

Hydroxycinnamic acids and phenolic enhancers raise rebaudioside solubility in water, enabling stable sweetener formulations without high heating.

Nonsteroidal glucocorticoid receptor antagonists lower elevated NLR in cancer patients and can improve response to chemotherapy or immunotherapy.

Branched lipid valency and hydrophobic chain tuning improve siRNA stability, clearance, and tissue-specific accumulation beyond conventional conjugates.

Targeted α1A-AR agonists protect mitochondria, reduce ROS production, and improve cardiac function in right ventricular failure.

A G1T38 oral dosing regimen limits steady-state exposure to maintain CDK4/6 efficacy while reducing neutropenia and gastrointestinal toxicity.

Microalgae extracellular vesicles carry antigens or RNA to gut and spleen tissues, improving vaccine delivery and immune modulation.

A cellulose-based suspending agent with polysorbate helps aripiprazole particles resist settling and stay easily redispersible during storage.

Lipid-linked CpG compounds improve lymph node delivery of HPV proteins to trigger antitumor immune responses in HPV-related cancers.

Maleate and fumarate polymorphs improve CDK9 inhibitor stability for pharmaceutical use while preserving treatment potential for CDK9-related diseases.

Piperazine-bridged heterocyclic pyrimidines improve KRAS G12D binding and suppress downstream signaling, cell proliferation, and tumor growth.

Intranasal lipophilic testosterone prodrugs raise CNS exposure while keeping systemic levels low to ease ADT side effects without weakening cancer control.

S1P and heparin are combined to restore endothelial glycocalyx thickness, reduce inflammation, and prevent early vascular damage.

Oxidative stress-triggered disulfide nanoparticles enable sustained ocular delivery of tyrosine kinase inhibitors with targeted release and low toxicity.

A bicyclic MAT2A inhibitor exploits MTAP deficiency to suppress tumor growth while reducing harmful effects on normal cells.

Prodrug steroid receptor compounds improve selective inhibition of hormone-dependent tumors while minimizing enzyme induction and toxicity.

Using enriched S- or R-bupropion instead of racemate improves pharmacokinetics and raises dextromethorphan plasma levels for CNS treatment.

A single butyrate-producing Christensenella strain simplifies microbiota therapy and helps improve glucose tolerance, insulin sensitivity, and liver weight.

A layered coated bead delays one stimulant dose to the distal intestine while releasing another immediately, extending ADHD coverage and resisting alcohol-induced release.

Compounds block NLRP3 ATPase activity to curb cytokine release and inflammation while reducing cardiotoxicity risk in treatment.

Crystalline lysine and histidine fosfomycin salts improve injectable solubility and bioavailability while avoiding the high sodium load of disodium forms.

A novel pyrazole derivative inhibits ROS production to reduce oxidative damage and support treatment of oxidative stress-related diseases.

Silencing MARC1 with RNAi plus GLP-1 or GLP-1/GIP agonists helps sustain weight loss and limit rebound after treatment stops.

Persulfides such as glutathione trisulfide suppress abnormal CD4+ T cell activation and proliferation in bowel and airway inflammation.

Structural changes to ferrostatin derivatives improve solubility, radical trapping, and plasma availability while preserving potent ferroptosis inhibition.

Combining a PPAR-gamma agonist, surfactant peptides, and phospholipids helps treat infant RDS while protecting lungs from hyperoxia injury.

Aseptically filled azithromycin premix uses pH buffering to avoid terminal sterilization while preserving refrigerated IV stability.

Novel formula (I) compounds selectively inhibit ERAP2 to tune antigen presentation and reduce autoimmune pathology while preserving immune surveillance.

Self-assembled block copolymers protect biologics while tuning charge, degradation, and targeting to reduce toxicity and immune response.

A lipid-alginate coating protects arginine granules from gastric acid, masks taste, and enables slower intestinal release for better bioavailability.

A combined GPEA, L-carnitine, and orotic acid composition reduces oxidative stress and supports neural cell viability and mitochondrial function.

Piperazine-based AR antagonists inhibit receptor activity and expression to address Enzalutamide resistance in castration-resistant prostate cancer.

Small molecules selectively inhibit ASH1L to curb oncogenic gene expression and proliferation while limiting toxicity to normal cells.

Defined crystal forms and pharmaceutically acceptable salts improve BET inhibitor stability and bioavailability through controlled crystallization.

Crystalline buprenorphine suspensions and matrix formulations enable sustained release with high bioavailability while minimizing injection-site irritation.

Primase/polymerase amplification and rolling-circle processing produce closed linear DNA with high fidelity, scalable yield, and cleaner non-viral delivery.

Sequence-specific dsRNA silences APOC3 through RNAi to lower triglyceride levels while limiting off-target effects and immunogenicity.

Formula I compounds selectively modulate TLR8 to stimulate immune responses while reducing off-target liabilities in disease treatment.

AAV9 delivers artificial miRNAs to the CNS to lower huntingtin mRNA and protein levels while improving motor function in Huntington's disease.

A lipid famotidine insert inside an antacid gel chewable blocks moisture and alkaline contact while enabling faster gastric symptom relief.

Targeting the IDH catalytic domain with gem-disubstituted heterocycles blocks 2-hydroxyglutarate formation and helps curb tumorigenic signaling.

A multi-step catalytic synthesis raises CRAC channel inhibitor yield and purity while keeping the process controlled for clinical testing.

Natural megakaryocyte-derived vesicles deliver FA genes or proteins with lower immunogenicity and improved chromosomal stability.

Sequence-designed polynucleotides bind TDP-43-like proteins to curb aggregation and inclusions linked to ALS and FTD progression.

A low-dose flumazenil and naltrexone combination improves depression, anxiety, and PTSD symptoms while reducing multi-drug burden.

A crystalline menin inhibitor composition blocks the menin-MLL interaction to improve targeted leukemia treatment in AML and ALL.

Camptothecin-linked anti-HER2 ADCs improve tumor targeting, limit non-specific release, and retain potency in resistant cancers.

Low-concentration chondroitin sulfate eye drops relieve ocular pain and post-surgical discomfort without steroid-related blurred vision.

An aqueous ticagrelor cyclodextrin complex enables stable IV delivery with full bioavailability for rapid treatment of Gram-positive bacteremia.

Iron oxide core nanoemulsions protect RNA, improve delivery efficiency, and enable MRI tracking while supporting stronger adaptive immune responses.

Solid API-cyclodextrin microparticles in eye drops raise dissolved drug concentration, improve ocular bioavailability, and limit impurities.